Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.ASH 2021
π₯ @DrAEvens of @RutgersCancer shares insights into the HoLISTIC Consortium, a global NIH-funded initiative that has aggregated data from over 30,000 patients with #HodgkinLymphoma.
Learn more by clicking here:
π π
#18ICML #LYMsm #Lymphoma #HemOnc
Insights into the HoLISTIC Consortium & the value of this initiative
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares insights into the HoLISTIC Consortium, a ...
ow.ly
It was a pleasure to speak with the lovely @helgasimonm of @amsterdamumc at #iwCLL2025 to hear about her work investigating the metabolic fitness of T-cells in patients with CLL.π©Έπ¬
Click here to learn more:
π π
#CLLsm #Leusm #Leukemia #ImmunoOncβ¦
Investigating the metabolic fitness of T-cells in patients with CLL
In this video, Helga Simon-Molas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, discusses her work i...
ow.ly
We recently spoke with @aaronchengmd (@PennMedicine), who shared insights from an analysis of morbidity rates in adults with non-transfusion-dependent #thalassemia referred to three US specialty centers.
Watch the interview here:
π π
#Hematology
Examining the morbidity rate in adults with NTDT referred to US specialty centers
Aaron Cheng, MD, University of Pennsylvania, Philadelphia, PA, discusses the high morbidity rate in adults with non-tr...
ow.ly
At #SOHO2025, we spoke with @khouri_jack of @ClevelandClinic, who discussed the safety & efficacy of the novel BCL-2 inhibitor lisaftoclax in different combinations for patients with #MultipleMyeloma or AL #amyloidosis.π©Έ
Watch the interview here:
π πβ¦
Lisaftoclax combinations in R/R myeloma and AL amyloidosis
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses the safety and efficacy of the novel BCL-2 inhibitor lis...
ow.ly
It was a pleasure to hear from Paolo Strati (@MDAndersonNews), Evandro Bezerra (@ClevelandClinic) & Andrew Jallouk (@VUMChealth), who took part in an engaging discussion on the role of CAR T-cells & transplant in LBCL.
Check out this fantastic discussion below:β¦
ASH 2021
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.π₯ @DrAEvens of @RutgersCancer shares insights into the HoLISTIC Consortium, a global NIH-funded initiative that has aggregated data from over 30,000 patients with #HodgkinLymphoma.
Learn more by clicking here:
π π
#18ICML #LYMsm #Lymphoma #HemOnc
Insights into the HoLISTIC Consortium & the value of this initiative
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares insights into the HoLISTIC Consortium, a ...
ow.ly
It was a pleasure to speak with the lovely @helgasimonm of @amsterdamumc at #iwCLL2025 to hear about her work investigating the metabolic fitness of T-cells in patients with CLL.π©Έπ¬
Click here to learn more:
π π
#CLLsm #Leusm #Leukemia #ImmunoOncβ¦
Investigating the metabolic fitness of T-cells in patients with CLL
In this video, Helga Simon-Molas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, discusses her work i...
ow.ly
We recently spoke with @aaronchengmd (@PennMedicine), who shared insights from an analysis of morbidity rates in adults with non-transfusion-dependent #thalassemia referred to three US specialty centers.
Watch the interview here:
π π
#Hematology
Examining the morbidity rate in adults with NTDT referred to US specialty centers
Aaron Cheng, MD, University of Pennsylvania, Philadelphia, PA, discusses the high morbidity rate in adults with non-tr...
ow.ly
At #SOHO2025, we spoke with @khouri_jack of @ClevelandClinic, who discussed the safety & efficacy of the novel BCL-2 inhibitor lisaftoclax in different combinations for patients with #MultipleMyeloma or AL #amyloidosis.π©Έ
Watch the interview here:
π πβ¦
Lisaftoclax combinations in R/R myeloma and AL amyloidosis
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses the safety and efficacy of the novel BCL-2 inhibitor lis...
ow.ly
It was a pleasure to hear from Paolo Strati (@MDAndersonNews), Evandro Bezerra (@ClevelandClinic) & Andrew Jallouk (@VUMChealth), who took part in an engaging discussion on the role of CAR T-cells & transplant in LBCL.
Check out this fantastic discussion below:β¦
Popular videos
View all
Press Briefings
View all
Multiple Myeloma
View all
Lymphoma
View all
Acute Myeloid Leukemia
View all
Acute Lymphoblastic Leukemia
View all
Myelodysplastic Syndromes
View all
Chronic Lymphocytic Leukemia
View all
Myeloproliferative Neoplasms
View all
CAR-T & Cellular Therapy News
View all
